Stock 688073 BIDE PHARMATECH CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Bide Pharmatech Co., Ltd.

Equities

688073

CNE100005NV3

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-07-14 pm EDT 		5-day change 1st Jan Change
29.62 CNY -4.85% Intraday chart for Bide Pharmatech Co., Ltd. -0.37% -46.63%
Jul. 09 Tranche Update on Bide Pharmatech Co., Ltd.'s Equity Buyback Plan announced on December 9, 2023. CI
Jul. 05 Bide Pharmatech Co., Ltd.'s Equity Buyback announced on December 9, 2023, has closed with 2,554,024 shares, representing 2.82% for CNY 99.99 million. CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
BIDE PHARMATECH CO., LTD. Stock Bide Pharmatech Co., Ltd.
-46.63% 362M -
MODERNA, INC. Stock Moderna, Inc.
+22.15% 46.56B
B-
LONZA GROUP AG Stock Lonza Group AG
+44.76% 41.67B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.37% 41.16B
B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+33.84% 32.4B
B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+20.42% 28.18B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-6.35% 28.1B
C
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+48.83% 14.52B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+45.00% 13.74B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.06% 12.17B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 688073 Stock
  4. Ratings Bide Pharmatech Co., Ltd.